Navigation Links
CorNova(R) Expands Management Team with Appointment of Robert Gallahue as Chief Financial Officer

Company Also Names Richard Sahagian as Senior Scientist

BURLINGTON, Mass., Feb. 17 /PRNewswire/ -- CorNova(R), Inc. today announced the expansion of its executive team with the appointment of Robert Gallahue as chief financial officer. The company also announced the addition of Richard Sahagian as senior scientist.

(Logo: )

The appointments reflect the evolution of the company's endovascular product line, which includes the FiberHalo(TM) stent deployment and post-dilatation balloon catheter, the FiberHalo(TM) pre-dilatation balloon catheter and the advanced Valecor Platinum(TM) Coronary Stent System.

"We needed to put in place the financial expertise required to move CorNova(R) closer to becoming an advanced development and commercial organization," said S. Eric Ryan, M.D., CorNova(R)'s chief executive officer. "Bob's depth of financial experience and knowledge of the biomedical industry will be a significant contribution to the growth and maturation of the company."

Gallahue, 48, has more than 20 years of financial management experience with public and private biotechnology and medical technology companies at various stages of clinical and commercial development. He has also successfully participated in a variety of financial transactions, including initial public offerings, mergers, joint ventures, private placements and follow-on offerings at a number of healthcare companies, including Molecular Insight Pharmaceuticals, Keryx Biopharmaceuticals and LeukoSite. He holds an M.S.A. from Bentley College and a B.A. from Middlebury College.

Sahagian, 46, has more than 20 years of experience in medical device development and production. He will be responsible for production of the Valecor Platinum(TM) Coronary Stent (a platinum surface-modified stent), as well as manage the research and development of advanced surface modification technologies. Prior to joining CorNova(R), Sahagian founded the medical device division at Implant Sciences Corp. He earned his B.S. from the University of Lowell.

About CorNova(R)

CorNova(R) is a developer of next-generation endovascular products designed to integrate new technologies into existing products and procedures resulting in better patient outcomes without added procedure time, cost and patient risk. The company's FiberHalo(TM) stent deployment and post-dilatation balloon catheter is designed for stent deployment, lumen area measurement and post-dilatation to be performed with a single catheter. CorNova(R) is also developing a pre-dilatation form of the FiberHalo that can obtain information on arterial plaque composition allowing for better physician decision making and the Valecor Platinum(TM) Coronary Stent, a platinum surface-modified bare-metal stent, that has shown superior performance and anti-restenosis properties compared to current bare-metal stents. For more information, visit

SOURCE CorNova, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix
2. Diplomat Specialty Pharmacy Expands National Hemophilia & IVIG Program
3. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
4. Yourway Transport Expands Biological Services
5. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
6. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
7. Yourway Transport Expands
8. MDV Expands Team Pursuing Advances in Personalized Medicine
9. Voler Expands Medical Device Design Capabilities
10. deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke
11. Avid Bioservices Expands Capabilities With Installation of Innovative Thermo Scientific HyClone Single-Use Bioreactor Systems
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society ... one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The ... where ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... Chief Financial Officer, will participate in the Piper Jaffray 27 th ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. EST ...
Breaking Biology Technology:
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
Breaking Biology News(10 mins):